Insight Molecular Diagnostics Inc.
Status: Publicly traded
Direct answer
Insight Molecular Diagnostics Inc. is publicly traded on NASDAQ under the ticker IMDX.
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung,...
Can you invest in Insight Molecular Diagnostics Inc.?
Yes. Insight Molecular Diagnostics Inc. is publicly traded on NASDAQ under the ticker IMDX.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Insight Molecular Diagnostics Inc.
Detailed equity research is provided by MarketSnap.